Important Notice to REGENXBIO Shareholders: Lead Plaintiff Deadline Approaches
In a recent announcement from The Gross Law Firm, shareholders of REGENXBIO Inc. (NASDAQ: RGNX) were alerted about a significant lead plaintiff deadline approaching on April 14, 2026. This notice is aimed at investors who purchased REGENXBIO shares during a specific period, enabling them to explore options for legal recourse related to recent developments within the company.
The designated class period for this suit extends from February 9, 2022, to January 27, 2026. During this time, shareholders are encouraged to reach out to the firm about the possibility of being appointed as lead plaintiffs. It's important to note that one does not need to be appointed as a lead plaintiff to benefit from any potential recovery stemming from this case.
The ongoing lawsuit primarily revolves around allegations that REGENXBIO provided misleading and incomplete information regarding its investigational gene therapy, RGX-111. Designed for treating severe Mucopolysaccharidosis Type I—commonly known as Hurler syndrome— the therapy came under scrutiny following concerning trial results. The complaint highlights that while the company made optimistic claims about RGX-111’s trial success based on favorable safety data, significant adverse information was allegedly concealed from investors.
On January 28, 2026, REGENXBIO faced a severe setback when it issued a press release announcing that the FDA had placed a clinical hold on RGX-111 after discovering an intraventricular central nervous system tumor in a participant from the ongoing Phase I/II clinical study. This shocking announcement resulted in a dramatic 17.8% drop in REGENXBIO's stock price, falling from $13.41 to $11.01 per share within 24 hours. This steep decline has drawn significant concern among investors who feel misled about the safety and viability of RGX-111.
Given the circumstances, it’s critical for shareholders of REGENXBIO to register for this class action promptly. The process of registration is straightforward and entails providing personal details through The Gross Law Firm’s online platform. Upon registration, shareholders will have access to portfolio monitoring software, which keeps them updated about the case's progress throughout its duration.
With the lead plaintiff deadline set for April 14, 2026, there is no time to lose for those who feel they have been adversely affected by these events. The Gross Law Firm is committed to advocating for the rights of all investors who have faced losses due to falsehoods and illicit business practices by companies. The firm specializes in class action lawsuits and aims to hold such companies accountable to uphold responsible business conduct.
In conclusion, if you are a REGENXBIO shareholder who purchased shares during the operational period and believe you were affected by the company's misleading statements regarding RGX-111, it is crucial to take action. The Gross Law Firm is ready to assist you in navigating this matter and ensure your voice is heard in the pursuit of justice.
The designated class period for this suit extends from February 9, 2022, to January 27, 2026. During this time, shareholders are encouraged to reach out to the firm about the possibility of being appointed as lead plaintiffs. It's important to note that one does not need to be appointed as a lead plaintiff to benefit from any potential recovery stemming from this case.
The ongoing lawsuit primarily revolves around allegations that REGENXBIO provided misleading and incomplete information regarding its investigational gene therapy, RGX-111. Designed for treating severe Mucopolysaccharidosis Type I—commonly known as Hurler syndrome— the therapy came under scrutiny following concerning trial results. The complaint highlights that while the company made optimistic claims about RGX-111’s trial success based on favorable safety data, significant adverse information was allegedly concealed from investors.
On January 28, 2026, REGENXBIO faced a severe setback when it issued a press release announcing that the FDA had placed a clinical hold on RGX-111 after discovering an intraventricular central nervous system tumor in a participant from the ongoing Phase I/II clinical study. This shocking announcement resulted in a dramatic 17.8% drop in REGENXBIO's stock price, falling from $13.41 to $11.01 per share within 24 hours. This steep decline has drawn significant concern among investors who feel misled about the safety and viability of RGX-111.
Given the circumstances, it’s critical for shareholders of REGENXBIO to register for this class action promptly. The process of registration is straightforward and entails providing personal details through The Gross Law Firm’s online platform. Upon registration, shareholders will have access to portfolio monitoring software, which keeps them updated about the case's progress throughout its duration.
With the lead plaintiff deadline set for April 14, 2026, there is no time to lose for those who feel they have been adversely affected by these events. The Gross Law Firm is committed to advocating for the rights of all investors who have faced losses due to falsehoods and illicit business practices by companies. The firm specializes in class action lawsuits and aims to hold such companies accountable to uphold responsible business conduct.
In conclusion, if you are a REGENXBIO shareholder who purchased shares during the operational period and believe you were affected by the company's misleading statements regarding RGX-111, it is crucial to take action. The Gross Law Firm is ready to assist you in navigating this matter and ensure your voice is heard in the pursuit of justice.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.